July 2, 2015

BIIB054 reached significant milestone

BIIB054, a drug candidate that was discovered by Neurimmune and acquired by Biogen in 2010, has reached a significant milestone of initiation of a Phase 1 clinical trial of BIIB054. BIIB054 is a human recombinant monoclonal antibody targeting alpha-synuclein, a target that is believed to play a central role in Parkinson's disease.